Eris Lifesciences Q1 FY27 call July 29, 2026 at 4:30 PM

Event at a glance

Eris Lifesciences Limited (NSE: ERIS) has scheduled an analyst and investor conference call for Wednesday, July 29, 2026 at 4:30 PM IST. The discussion is intended to cover the company’s standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, which corresponds to Q1 FY2027. The company said the results are subject to approval by its Board of Directors. Participation will be hosted through a Zoom webinar, and attendees must pre-register to join. The company has linked the event to Regulation 30 of the SEBI (LODR) Regulations, 2015.

What Eris Lifesciences said the call will cover

The company stated that the conference call is being organised after the Board meeting that will consider and approve the standalone and consolidated unaudited Q1 FY27 results. This structure is typical for companies that want to address analyst questions soon after publishing quarterly numbers. The call is open to analysts, institutional investors, and other market participants. Eris Lifesciences also pointed participants to its website for full schedule and access information.

How to join: Zoom pre-registration is required

Eris Lifesciences has asked interested analysts and investors to pre-register via Zoom. The registration is required to access the webinar discussion. The company provided a Zoom webinar registration link: https://zoom.us/webinar/register/WN_AH5SYmDJSu6TzrMoYbS9pg. It also said its Investor Relations department is coordinating logistics and requested RSVP from participants. The Investor Relations contact named in the announcement is Atul Modi, reachable at [email protected].

Key schedule and access details

What the disclosure indicates about governance and timing

Eris Lifesciences said the meeting and call are scheduled pursuant to Regulation 30 of SEBI’s LODR framework, which deals with material disclosures. The company also specified that the board meeting is scheduled for July 29, 2026 to approve the standalone and consolidated unaudited Q1 FY27 results. The earnings call is set for the same day at 4:30 PM IST to discuss those results. From an investor communications perspective, this sequencing suggests the company intends to address questions promptly after the board considers the quarterly financials.

Guidance and operating priorities mentioned alongside the event

Alongside the call announcement, the provided information includes Eris Lifesciences’ FY27 guidance targeting 18-20% revenue growth and stable EBITDA margins, with an ambition to grow at 1.3 times the CVM (Chronic Value Market). The company’s guidance for its Domestic Branded Formulations (DBF) segment cited a FY26 base revenue of ₹2,778 crore, with a targeted FY27 DBF EBITDA margin of 37%. Separately, the company’s Q1FY26 corporate presentation data referenced a Moving Annual Total (MAT) revenue of ₹3,318 crore for the period ending March 2026.

Recent financial snapshot provided in the dataset

The article data also includes “Quick Details” and other snapshots that provide context ahead of the Q1 FY27 results. These include a previous quarter revenue of ₹756.56 crore, previous quarter PAT of ₹279.10 crore, and a previous quarter EBITDA margin of 36.15%. The same snapshot lists net debt (latest quarter) at ₹2,242 crore, market capitalisation at ₹19,415.57 crore, and a CMP of ₹1,400.6. A separate market snapshot line shows the stock at 1,417.00, down 23.60 (-1.64%), with 1-year returns shown as -20.20%.

Other disclosed items: dividend and debt servicing

The dataset notes that the company announced an interim dividend of ₹7.21 per fully paid-up equity share of face value ₹1 for FY2026-27. It also states that Eris Lifesciences completed routine interest servicing on outstanding Non-Convertible Debentures totalling ₹109.12 crore on June 8, 2026. The note adds that the payment covered two tranches of ₹625 crore each, with a net payout of ₹105.99 crore after TDS.

Why this earnings call matters for investors

For analysts and institutional investors, the July 29 call is a defined forum to hear management commentary on Q1 FY27 performance once the board approves the results. With the company having stated FY27 guidance of 18-20% revenue growth and stable EBITDA margins, the Q1 FY27 print and management remarks can help market participants evaluate execution against these targets. The call also provides an opportunity to seek clarity on segment-level performance and how the company plans to pursue its stated ambition of growing at 1.3 times the CVM. Since participation requires pre-registration, investors who want to listen in should complete Zoom registration ahead of time.

What to watch next

Eris Lifesciences has set July 29, 2026 as the key date for both the board meeting to consider Q1 FY27 numbers and the subsequent investor call at 4:30 PM IST. Interested participants can use the company-provided Zoom link to pre-register for access. Additional details are available on the company’s website: https://eris.co.in/.